News and Trends 11 Sep 2019 IBM’s Watson for Genomics Launches in First European Hospital The Hôpitaux Universitaires Genève in Switzerland will be the first European university hospital to implement IBM’s artificial intelligence to help doctors select treatments for complex cancer cases. “Artificial intelligence could empower our clinicians to increase the speed of diagnosing their patients,” said Rodolphe Meyer, who is responsible for the IT department of […] September 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […] August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […] May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2019 Swiss Multi-Cancer Diagnostic Test Approved in Europe A cancer test developed by the Swiss company SOPHiA GENETICS has been approved for diagnosing multiple types of solid tumors by looking at genetic variations in 42 genes. SOPHiA GENETICS works in data-driven medicine, using huge amounts of genomic data to diagnose and personalize treatments to a patient. This new technology is being adopted by […] April 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019 Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t respond to checkpoint inhibitor drugs. In the last five years, checkpoint inhibitor drugs have become a potentially life-saving option for people that don’t respond to traditional cancer treatments. These antibody drugs have shown promise in […] March 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of Oxford-based […] March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2019 Artificial Intelligence Detects Juvenile Arthritis in the Blood Using artificial intelligence, a Belgian research group can diagnose juvenile arthritis from blood samples with almost 90% accuracy and identify different forms of the disease, something that is not currently possible. Juvenile idiopathic arthritis causes joint pain, swelling and stiffness in children under the age of 16. The disease is hard to treat because there […] March 13, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2019 AI Drug Discovery Company Raises €23M and Signs with Roche Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with Roche worth up to €60M. Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech. “We can reduce at least 4- to 5-fold the time and cost of drug discovery as compared to the industry […] January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2019 Swiss Firm Raises €67M to Take Genomics AI to Hospitals SOPHiA GENETICS has completed a $77M (€67M) funding round that will expand the use of its artificial intelligence technology for genomics into hospitals across the world. The funding will mainly go towards the recruitment of new employees. The goal is to increase the number of hospitals using SOPHiA’s AI technology, particularly in the US, where […] January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2018 British Company Raises €37M to Personalize Therapies with Machine Learning Genomics, a company based in Oxford, has increased the amount raised in a Series B round that will fund further development of its genomics technology for personalized medicine. The company adds a further €9M (£8M) to the round with the participation of Foresite Capital and F-Prime Capital, two renowned US life sciences investors. The previous […] December 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2018 Microsoft Signs its First Microbiome Partnership Microsoft Genomics will work with Cambridge-based Eagle Genomics to scale up its artificial intelligence platform for microbiome research. In recent years, it has become evident that the microbes that inhabit our body are key to our health. The microbiome has been linked to conditions such as diabetes, cancer, Alzheimer’s, multiple sclerosis and many more. However, large-scale studies […] October 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2018 AI Company Raises €8.6M to Find Drugs for Rare Diseases Faster and Cheaper Than Ever Cambridge-based Healx has raised $10M (€8.6M) in a Series A round to scale up its AI technology, which could significantly reduce the time and cost of developing drugs for rare diseases. Backed, among other investors, by the founder of Abcam, Healx plans to use the fundraising to double its workforce from 15 to over 30 […] July 26, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email